EU/3/04/240

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in January 2019 at the end of the 12-year period of market exclusivity.

On 20 October 2004, orphan designation (EU/3/04/240) was granted by the European Commission to Eisai Limited, United Kingdom, for rufinamide for the treatment of Lennox-Gastaut syndrome.

Rufinamide has been authorised in the EU as Inovelon since 16 January 2007.

The sponsorship was transferred to Eisai GmbH - Germany, in June 2018.

Key facts

Active substance
Rufinamide
Disease / condition
Treatment of Lennox-Gastaut syndrome
Date of first decision
20/10/2004
Outcome
Expired
EU designation number
EU/3/04/240

Sponsor's contact details

Eisai GmbH
Lyoner Straße 36
60528 Frankfurt am Main
Germany
E-mail: medinfo_de@eisai.net

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating
Average
1 rating